Pharmacogenetics to Avoid Adverse Drug Reactions

doi:10.3390/books978-3-0365-3343-8

Reprint

Download Flyer

Pharmacogenetics to Avoid Adverse Drug Reactions

Edited by

February 2022

220 pages

ISBN978-3-0365-3344-5 (Hardback)
ISBN978-3-0365-3343-8 (PDF)

https://doi.org/10.3390/books978-3-0365-3343-8

Free download (PDF)

This book is a reprint of the Special Issue Pharmacogenetics to Avoid Adverse Drug Reactions that was published in

Medicine & Pharmacology

Public Health & Healthcare

Summary

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.

Format

Hardback

License

Keywords

5-fluorouracil; capecitabine; fluoropyrimidine; thymidylate synthase; thymidylate synthase enhancer region; upstream stimulatory factor 1; adverse drug reactions; pharmacogenomics; epistasis; random forest; statin; cardiovascular disease; colorectal cancer; adverse drug reactions; pharmacogenomics; personalised medicine; toxicity; (es)citalopram; drug-gene-interaction; drug-drug-interaction; drug-drug-gene-interaction; the PharmLines initiative; antipsychotic agents; pharmacogenetics; cytochrome P-450 enzyme system; psychotic disorders; precision medicine; direct oral anticoagulants; pharmacogenetics; adverse drug reactions; clinical implementation; atorvastatin; pharmacogenetics; SLCO1B1; precision medicine; HLA; cutaneous adverse drug reaction; SCAR; genetic polymorphism; antiepileptics; CYP450 enzymes; platelet reactivity; single-nucleotide variants; pharmacogenetics; acute coronary syndrome; clopidogrel; genotype; allele; polymorphism; HLA B; CYP2C9*3; cutaneous adverse drug reactions (CADRs); anti-epileptic drugs (AEDS); phenytoin (PHT); genetic risk factors; South India; India; pharmacogenetics; cardiology; adverse events; guidelines; n/a